Answers are grounded in this paper and cite their sources.
Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell-mediated killing by Tin and colleagues. See related article by Tin et al., p. 217.
No takes yet. Share an insight, caveat, or question.
Terry J. Fry (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: